# A dose-finding trial for exercise after cancer

Source: https://onco.cc/ideas/idea-nl-exercise-dose-finding/  
OnCo record `idea-nl-exercise-dose-finding` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CHALLENGE proved exercise works in colon cancer but not how much is needed. A trial comparing doses, as we would for a drug, would tell health systems what to fund.

## Summary

Drugs get dose-finding; exercise got a single dose (about 10 MET-hours/week above baseline) chosen from cohort data. Cohorts suggest a dose-response with benefit continuing beyond 18 MET-hours/week, but also that the first few hours matter most. Health systems deciding what to reimburse need to know whether a cheaper, lower-dose or unsupervised programme retains most of the benefit.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: In colon or breast cancer survivors, disease-free survival improves in a dose-dependent manner across 5, 10 and 20 MET-hours/week of supervised activity, with most of the benefit achieved at 10 MET-hours/week, and objectively measured adherence (wearables) rather than prescribed dose predicts outcome.
- Rationale: Dose-response evidence converts a single positive trial into a prescribable intervention, defines the minimum effective dose for resource-limited settings, and lets wearables substitute for self-report as the exposure measure.
- Proposed test: Three-arm randomised trial (n about 1,500) in stage II-III colon cancer after adjuvant chemotherapy with wearable-verified MET-hours, DFS primary endpoint, embedded cost-effectiveness and a biomarker sub-study (insulin, CRP, ctDNA).
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics: https://cancercontrol.cancer.gov/ocs/statistics

## Connected records

- ideas: [Pay for supervised exercise the way we pay for drugs](https://onco.cc/ideas/idea-bio2-exercise-reimbursement/), [Structured exercise prescribed like a drug in all curative-intent cancer care](https://onco.cc/ideas/idea-exercise-as-adjuvant/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [Diet, Exercise & Lifestyle](https://onco.cc/fronts/nutrition-lifestyle/)
- technologies: [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/), [Structured exercise programmes after curative treatment](https://onco.cc/technologies/structured-exercise-survivorship/)
- terms: [Energy balance](https://onco.cc/terms/energy-balance/), [MET-hours per week](https://onco.cc/terms/met-hours/)
- trials: [AMICO: aerobic or resistance exercise to improve outcome in metastatic colorectal cancer](https://onco.cc/trials/rejuv-trial-amico/), [CHALLENGE (CCTG CO.21)](https://onco.cc/trials/challenge/)
- bottlenecks: [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/)
- roadmaps: [Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment](https://onco.cc/roadmaps/nutrition-lifestyle-roadmap/), [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-nl-exercise-dose-finding.json